Arsenal-backed Endpoint Clinical acquires Bluefin
The clinical supply planning platform will remain independent and continue working with trial supply systems across the industry.
Arsenal Capital Partners-backed Endpoint Clinical acquired Bluefin, a Boston-based provider of clinical supply forecasting and planning software. Bluefin helps clinical trial sponsors and contract research organizations forecast demand, compare supply scenarios and plan distribution.
It will operate independently and continue connecting with randomization and trial supply management systems from other providers. Endpoint will provide global project management, implementation, quality and customer support. Arsenal acquired Endpoint in 2024.
Deal facts
- Target
- Bluefin
- Acquirer
- Endpoint Clinical
- Backed by
- Arsenal Capital Partners
- Deal type
- Add-on
- Headquarters
- Boston, MA
- Status
- Completed
- Announced
- Monday, September 14, 2026
Sources
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.